NCT04964024

SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

SaRS-Cov-2 Antibodies Following Exposure to COVID-19 and/or Vaccination in Nursing Homes

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,293 (actual)
• Sponsor: Central Hospital, Nancy, France · Academic / Other
• Sex: All
• Age: 20 Years – 110 Years
• Healthy volunteers: Accepted

Summary

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease. Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study

Conditions

• COVID-19 Infection

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	SARS-CoV-2 antibodies	Analysis of the results of the serological response to COVID-19 and/or Vaccine

Timeline

• Start date: 2021-07-15
• Primary completion: 2022-05-15
• Completion: 2022-05-15
• First posted: 2021-07-15
• Last updated: 2022-07-19

Locations

1 site across 1 country: France